Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Carcinoma, Non-Small-Cell Lung 8Leukemia, Myeloid, Acute 6Neoplasm Metastasis 4Leukemia, Myelomonocytic, Acute 4Leukemia, Monocytic, Acute 4Leukemia, Megakaryoblastic, Acute 4Leukemia, Erythroblastic, Acute 4Lung Neoplasms 3Endometrial Neoplasms 3Congenital Abnormalities 3Colonic Neoplasms 3Breast Neoplasms 3Sarcoma 2Oropharyngeal Neoplasms 2Neuroblastoma 2Melanoma 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Leukemia, Lymphocytic, Chronic, B-Cell 2Leukemia, Eosinophilic, Acute 2Leukemia, Basophilic, Acute 2Leukemia 2Colorectal Neoplasms 2Carcinoma, Hepatocellular 2Brain Neoplasms 2Anus Neoplasms 2Ureteral Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Stage I Mixed Cell Type Kidney Wilms Tumor 1

Interventions

Lenalidomide 3daratumumab 2Dexamethasone 2dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1Watchful Waiting 1Stem Cell Transplantation 1Peripheral Blood Stem Cell Transplantation 1Observation 1Melphalan 1Maintenance 1Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Smoldering Multiple Myeloma × Observation × Clear all
NCT01169337 2026-05-01

Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
226 enrolled 16 charts
Plasma cell

Smoldering Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡